<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334591</url>
  </required_header>
  <id_info>
    <org_study_id>HYF001</org_study_id>
    <nct_id>NCT03334591</nct_id>
  </id_info>
  <brief_title>Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer</brief_title>
  <official_title>Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anhui Provincial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hope that after this research, two different treatment methods' curative
      effects for advanced gastric cancer can be assessed. One is continuous use of apatinib, the
      other is 5 days' continuous use and 2 days' off of apatinib.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progress free survival(PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>From data of randomization until the date of first dccumentde progression or date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>disease control rate (DCR)</measure>
    <time_frame>1year</time_frame>
    <description>investigators will assess treatment response according to Response Evaluation Criteria in Soid Tumor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response rate(ORR)</measure>
    <time_frame>1year</time_frame>
    <description>difined as the percentage of subjects having achieved confirmed Complete Response+Partial Response as best overall response according to radiological assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (os)</measure>
    <time_frame>1year</time_frame>
    <description>difined as the length of time from random assignment to death or to last contact</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>1 year</time_frame>
    <description>a questionnaire developed to assess the quality of life of cancer patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>adverse events are evaluated according to National Cancer institute Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Two Different Treatment Methods</condition>
  <arm_group>
    <arm_group_label>Apatinib 5 days' continuous use and 2 days' off</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500mg 5 days' continuous use and 2 days' off with Docetaxel60mg/m2 to treat advanced gastric cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apatinib 500mg continuous use</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apatinib 500mg continuous use with Docetaxel60mg/m2 to treat advanced gastric cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib 500mg with Docetaxel 60mg/m2</description>
    <arm_group_label>Apatinib 5 days' continuous use and 2 days' off</arm_group_label>
    <arm_group_label>Apatinib 500mg continuous use</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients,age≥18years

          2. Confirmed by Pathology or histology of Gastric cancer

          3. Patients who failed first-line chemotherapy

          4. The ECOG physical status score:0 to 2

          5. Expected survival ≥3months

          6. Patients should be voluntary to the trail and provide with signed informed consent.

          7. The researchers believe patients can benefit from the study.

        Exclusion Criteria:

          1. Pregnant or lactating women

          2. Patients with a knowm history of allergic reactions and/ou hypersensitivity attributed
             to apatinib or its accessories

          3. Patients with apatinib contraindications

          4. Patients of doctors considered unsuitable for the trail
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yifu He, doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Anhui Provincial Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>yifu He, doctor</last_name>
    <phone>0551-65327666</phone>
    <email>834638033@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Cancer Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yifu he, doctor</last_name>
      <phone>0551-65327666</phone>
      <email>834638033@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

